Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND)
Month 12 results from the real-world BEYOND study support the effectiveness of CAB + RPV LA for maintenance of virologic suppression and as a preferred treatment option for people with HIV-1.
Authors
- Dima Dandachi (ORCID: https://orcid.org/0000-0002-8641-0988)
- Deanna Merrill
- Cathy C. Schubert (ORCID: https://orcid.org/0000-0001-9341-1340)
- Ana M. Puga (ORCID: https://orcid.org/0000-0003-2836-4642)
- Kaitlin Nguyen (ORCID: https://orcid.org/0009-0001-8822-5380)
- Cindy Garris (ORCID: https://orcid.org/0000-0002-2685-1204)
- Gary Sinclair
- Doug Cunningham
- Bintu Sherif (ORCID: https://orcid.org/0000-0002-3251-0078)
- David B. Richardson (ORCID: https://orcid.org/0000-0002-6481-8851)
- L. Zografos
- Maria Reynolds (ORCID: https://orcid.org/0000-0002-2578-5188)
- Paula Teichner
- William M. Valenti
- Kate Nelson
Institutions
- Proteogenomics Research Institute for Systems Medicine (US)
- RTI Health Solutions (US)
- University of Rochester (US)
- University of Missouri (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1093/ofid/ofaf220
- Citations
- 7
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 9.77
Funders
- AIDS Healthcare Foundation
- Oklahoma State University
- University of Missouri
- Cleveland Clinic
- Cleveland Clinic Foundation
- ViiV Healthcare
- University of Illinois at Urbana-Champaign
- University of Illinois at Chicago
- School of Medicine, Indiana University
- Center for Health Sciences, Oklahoma State University